Skip to main content
Menu
Revvity logo
Contact us

Loading...

US
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • UK Tax Strategy Statement

UK Tax Strategy Statement

In compliance with the United Kingdom ("UK") Finance Act 2016, Schedule 19, paragraph 19, this UK Tax Strategy Statement sets out the approach of Revvity, Inc. ("Revvity" or "the Company") to managing the tax affairs of the Revvity affiliated entities operating in the UK (collectively the "UK Group").

This Tax Strategy Statement and all our underlying processes and controls in relation to our UK Group tax affairs have been approved by all appropriate directors and is subject to periodic review.

Overview of the Company

Revvity is a Massachusetts corporation, founded in 1947 and headquartered in Waltham, Massachusetts, USA. Revvity markets products and services in more than 150 countries. As of December 31, 2017, the Company employed approximately 11,000 employees in our continuing operations.

Revvity is a leading provider of products, services and solutions for the diagnostics, food, environmental, industrial, life sciences research and laboratory services markets. Through our advanced technologies and differentiated solutions, Revvity addresses critical issues that help to improve lives and the world around us.

The Company's common stock is listed on the New York Stock Exchange under the symbol "RVTY" and we are a component of the S&P 500 Index. As a multinational entity, Revvity is the ultimate parent company of all UK subsidiaries covered by this publication and as published in the Exhibit 21 before the Security Exchange Commission ("SEC").

A description of our principal product offerings and products are contained in our most recent Form 10-K filed with the SEC and can be accessed here.

Approach to Governance Management

Revvity conducts business with the highest ethical standards and is committed to honesty, integrity and fairness as set forth in the Company's Standard of Business Conduct  policy. Responsible business practices are ingrained in everything the Company undertakes and inherent in our core values and standards of business conduct. This approach is critical to the success of the Company and our ability to build and sustain relationships with each other, customers, partners and shareholders while delivering results Revvity is proud of.

Not only does Revvity's mission to innovate for a healthier world start with good corporate citizenship, it is contingent upon it. Our sound corporate governance practices and employee training programs ensure the Company is able to operate effectively, consistently and ethically within the global community.

Therefore, Revvity strives to apply high ethical, moral and legal principles in every aspect of business conduct and our relationships with public authorities and all employees, including those in the UK Group, must comply with the values in the aforementioned policy.

Approach to Tax Risk Management

Revvity's approach to taxes takes the above principles and values and applies them to corporate taxation. That said, as subsidiaries of the Company, the UK Group follows internal procedures and controls in agreement with the United States Sarbanes-Oxley Act of 2002.

To that extent and in order to assure compliance with current tax laws and regulations, all of the Company's policies and processes in relation to taxation are governed by aptly skilled individuals within our UK finance and legal teams with the adequate support from Revvity's Tax Department to ensure that all tax liabilities and obligations are reported and paid to the tax authorities in a timely manner.

In addition to the above, Revvity regularly revises and tests all the above obligations in the countries where we operate, including the UK. These internal controls are also subject to periodic external audit.

Having said the above, Revvity recognizes that given the size of our business and volume of tax obligations, risks inevitably arise from time to time in relation to the interpretation of tax laws and the nature of our tax compliance arrangements. Revvity proactively seeks to identify, evaluate, control and monitor these risks to ensure risk minimization. Where there is significant uncertainty or complexity in relation to a risk, external advice is sought.

In this regard, advice from external and expert consultants is often sought for a variety of reasons in respect of our approach to tax risk such as obtaining technical expertise or litigation support. Revvity only engages external advisers and consultants that share our values of accountability, integrity and good citizenship and understand our objectives. Any tax position and/or decision concerning to either compliance or planning is subject to the approval of the local management and the Tax Department.

Approach to Tax Planning

Revvity's tax strategy consists of paying the correct amount of tax due in the appropriate jurisdiction at the correct time within the legal deadlines established locally. When implementing our tax strategy, adequately balancing the underlying commercial purpose and economic substance of our activities is considered the most significant factor together with maximizing and creating value on a sustainable basis for our shareholders.

With these premises in mind, Revvity does not undertake planning that is strained or artificial or that which is purely tax driven and only considers tax strategies that we feel confident in discussing openly with tax authorities. This is part of the Company's attitude to build trust in the tax system during a period of continuous changes in the international tax arena.

Relationship with Tax Authorities - HMRC

Revvity's relationship with tax authorities is fluent and constant. Particularly, we conduct our relationship with the HMRC with openness and integrity to ensure compliance with its tax obligations, meet all applicable UK tax requirements and minimize the risk of interest and penalties. Since 2008, Revvity has been part of HMRC's program for Risk Status and Review of Links with Large Business (RLLB) having been scored always by HMRC as a low risk company.

Consequently, Revvity continues to resolve any matters through pro-active and transparent discussion and negotiation with HMRC recognizing that early resolution of risks is in the best interests of the Company and all tax authorities.  
 

    • All Policies
    • Privacy Policy
    • Website Terms & Conditions
    • Cookie Policy
    • Accessibility Statement
    • Employment Applicant and Candidate Privacy Notice
    • Unsolicited Submissions Policy
    • General Terms and Conditions of Sale - Global (English)
    • Terms & Conditions of Sale - Life Sciences Reagents
    • Terms & Conditions of Sale - Life Sciences Reagents CA (FR)
    • Terms & Conditions of Sale - Life Sciences (Horizon & Dharmacon Products & Services Only)
    • - Standard Terms & Condition of Sale Applicable to Services or Website Product Sales
    • - Licensing Statements
    • - Limited Use Label License for Engineered Cell Lines
    • Terms & Conditions of Sale - Gene Delivery (Legacy SIRION Biotech Products and Revvity Gene Delivery Products Only)
    • - General terms of sale and delivery for Revvity gene delivery GmbH
    • - Terms & conditions of sale of products for Revvity gene delivery, Inc.
    • Terms & Conditions of Sale - Australia
    • Terms & Conditions of Sale - Austria
    • Terms & Conditions of Sale - Belgium (Dutch)
    • Terms & Conditions of Sale - Belgium (French)
    • Terms & Conditions of Sale - Canada (English)
    • Terms & Conditions of Sale - Canada (French)
    • Terms & Conditions of Sale - Denmark
    • Terms & Conditions of Sale - Finland
    • Terms & Conditions of Sale - France
    • Terms & Conditions of Sale - Germany
    • Terms & Conditions of Sale - Ireland
    • Terms & Conditions of Sale - Italy
    • Terms & Conditions of Sale - Netherlands
    • Terms & Conditions of Sale - Norway
    • Terms & Conditions of Sale - Sweden
    • Terms & Conditions of Sale - Switzerland (French)
    • Terms & Conditions of Sale - Switzerland (German)
    • Terms & Conditions of Sale - UK
    • Terms & Conditions of Quotation / Sales Proposal - India (INR)
    • Terms & Conditions of Quotation / Sales Proposal - India (USD)
    • General Terms and Conditions of Service - Global (English)
    • Terms and Conditions of Service - Australia
    • Terms and Conditions of Service - Austria
    • Terms and Conditions of Service - Belgium (French)
    • Terms and Conditions of Service - Belgium (NL)
    • Terms and Conditions of Service - Brazil
    • Terms and Conditions of Service - Canada (French)
    • Terms and Conditions of Service - Denmark
    • Terms and Conditions of Service - Finland
    • Terms and Conditions of Service - France
    • Terms and Conditions of Service - Germany
    • Terms and Conditions of Service - Italy
    • Terms and Conditions of Service - Mexico
    • Terms and Conditions of Service - Netherlands
    • Terms and Conditions of Service - Norway
    • Terms and Conditions of Service - Spain
    • Terms and Conditions of Service - Sweden
    • Terms and Conditions of Service - Switzerland (French)
    • Terms and Conditions of Service - Switzerland (German)
    • Terms and Conditions of Service - UK
    • Custom Assay Development Services Terms & Conditions
    • Supplier Information Overview
    • Supplier Code of Conduct
    • Terms and Conditions of Purchase - North America
    • Terms and Conditions of Purchase - Groningen
    • Terms and Conditions of Purchase - APAC
    • Terms and Conditions of Purchase - Europe
    • UK Tax Strategy Statement
    • Italy - Privacy Policy
    • Italy - D.lgs 231/01
    • Privacy Policy
    • HIPAA Privacy Policy
    • Revvity (UK) Pension Scheme
    • Synthetic Nucleic Acid Framework Attestation
    • WEEE Directive Compliance Overview
    • Recycling of a Revvity Product
    • - Austria
    • - Belgium
    • - Denmark
    • - Finland
    • - France
    • - Germany
    • - Ireland
    • - Italy
    • - Luxembourg
    • - Netherlands
    • - Norway
    • - Poland
    • - Spain
    • - Sweden
    • - United Kingdom
    • Recyclers/Treatment Facilities
    • Decontamination of Instrumentation

Questions?
We're here to help.

Contact us
Revvity Logo

Loading...

    ©2025 Revvity - All rights reserved

    Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.